PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 9, 2026Journal of Global Antimicrobial Resistance1 citationsOpen Access

Efficacy and safety of antibiotics in the treatment of multidrug-resistant Acinetobacter baumannii infections: a systematic review and Bayesian network meta-analysis

View Full Paper
BTBinh Van TranTaipei Medical UniversityPHPhi Yen HuynhTaipei Medical UniversityTTTu Tuan TranThai Nguyen University

Key Points

  • This research aims to evaluate the efficacy and safety of various antimicrobial therapies for multidrug-resistant Acinetobacter baumannii infections.
  • Conducted a Bayesian network meta-analysis of randomized controlled trials and cohort studies.
  • Searched PubMed, Embase, Web of Science, Scopus, and Cochrane Library databases up to January 2025.
  • Included 10 RCTs and 38 cohort studies, involving 7,300 patients, assessing outcomes like mortality and nephrotoxicity.
  • Cefiderocol-based therapies reduced mortality compared to tigecycline (OR = 0.41, 95% CrI: 0.22–0.77) with very low certainty.
  • Sulbactam–durlobactam ranked highest for clinical improvement (OR = 5.79, 95% CrI: 1.62–21.46) and microbiological cure (OR = 8.66, 95% CrI: 1.92–41.01).
  • Colistin-based regimens showed the highest nephrotoxicity (combination: OR = 8.21; monotherapy: OR = 7.75; both with very low certainty).

Abstract

• Cefiderocol-based therapies ranked highest for mortality reduction. • Sulbactam–durlobactam ranked first for clinical and microbiological cure. • Most evidence was derived from cohort studies with very low certainty. • Findings cannot substitute for randomized comparisons. • baumannii -specific trials are needed to validate these findings. This study aims to compare the efficacy and safety of antimicrobial regimens for multidrug-resistant Acinetobacter baumannii (MDR A. baumannii ) infections using a Bayesian network meta-analysis (NMA). The PubMed, Embase, Web of Science, Scopus, and Cochrane Library databases were searched from inception through 6 th January 2025, for randomized controlled trials (RCTs) and cohort studies. The primary outcome was all-cause mortality; secondary outcomes included clinical improvement, microbiological cure, and nephrotoxicity. A random-effects NMA estimated odds ratios (ORs) with 95% credible intervals (CrIs) and ranked regimens using the surface under the cumulative ranking curve (SUCRA). The Bayesian NMA included 10 RCTs and 38 cohort studies (14 regimens; 7,300 patients), with cohorts contributing 80.6% of the data. Compared with tigecycline, cefiderocol-based therapies (combination: OR = 0.41, 95% CrI: 0.22–0.77; monotherapy: OR = 0.44, 95% CrI: 0.27–0.76) and sulbactam–durlobactam (OR = 0.42, 95% CrI: 0.15–1.20) were associated with reduced mortality (very low certainty). Sulbactam–durlobactam also ranked highest for clinical improvement (OR = 5.79, 95% CrI: 1.62–21.46, SUCRA 91.0%) and microbiological cure (OR = 8.66, 95% CrI: 1.92–41.01, SUCRA 98.2%; very low certainty). Colistin-based regimens had the highest nephrotoxicity (combination: OR = 8.21, 95% CrI: 1.41–59.35; monotherapy: OR = 7.75, 95% CrI = 1.81–40.82; very low certainty). Sulbactam–durlobactam ranked highest for clinical improvement and microbiological cure, while cefiderocol-based therapies scored highest for mortality reduction in our NMA. However, the evidence was largely derived from observational studies with very low certainty. Further A. baumannii -specific RCTs are needed to confirm these findings.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Tran et al. (2026) studied this question.

synapsesocial.com/papers/69fecf49b9154b0b82876408https://doi.org/10.1016/j.jgar.2026.04.016
Ask AI
Helpful
Bookmark
Share
View Full Paper